Because MM mainly affects elderly people and MM bone disease seems to be a reflection of osteoblast deactivation resulting from myeloma cell secretion of Wnt inhibitors such as DKK1 [16], [33], we hypothesize that daily administered PTH will help control disease progression indirectly by stimulating bone formation. This evidence concerns the gene DKK1 and plasma cell myeloma.